Therapeutic Kinase Inhibitors - nouveau livre

Livre dans la base de données depuis 2012-12-03T21:22:03+01:00 (Paris)
Page de détail modifiée en dernier sur 2023-10-25T14:54:19+02:00 (Paris)
ISBN/EAN: 9783642282966

ISBN - Autres types d'écriture:
3-642-28296-2, 978-3-642-28296-6
Autres types d'écriture et termes associés:
Auteur du livre: sawyer, mell, mellin, melling, grabinski
Titre du livre: kina kina

Données de l'éditeur

Auteur: Ingo K. Mellinghoff; Charles L. Sawyers
Titre: Current Topics in Microbiology and Immunology; Therapeutic Kinase Inhibitors
Editeur: Springer; Springer Berlin
234 Pages
Date de parution: 2012-11-27
Berlin; Heidelberg; DE
Langue: Anglais
149,79 € (DE)
154,00 € (AT)
177,00 CHF (CH)
Available
X, 234 p.

EA; E107; eBook; Nonbooks, PBS / Medizin/Nichtklinische Fächer; Onkologie; Verstehen; Mitogen Activated Protein Kinase (MAPK); Raf kinases; biomarkers; chemical library; clinical trial design; drug development; drug efficacy; epigenetics; gastrointestinal stromal tumor (GIST); genetically engineered mouse models (GEMMs); glioblastoma; lung adenocarcinoma; lung cancer; melanoma; myeloproliferative neoplasms; small molecules; B; Cancer Biology; Biomedical and Life Sciences; BB

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. 

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. 

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert.